Treatment for Atrial Fibrillation

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Oregon Health & Science University (OHSU), Portland, OR
Atrial Fibrillation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Atrial fibrillation (AF) is the most common arrhythmia in the world, with significant morbidity and mortality. With appropriate oral anticoagulation, the risk of stroke due to atrial fibrillation decreases by 64%. Although atrial fibrillation is commonly diagnosed and treated in the Emergency Department (ED), oral anticoagulation is significantly underprescribed. Underprescribing has been attributed to a lack of empowerment and deferral of prescribing to longitudinal care clinicians. Using a convergent parallel quantitative-qualitative design (mixed-methods), we propose a stepped-wedge cluster randomized trial design with the implementation of a clinical decision support (CDS) tool in adults with new-onset AF that are OAC-naïve and at significant risk for stroke. In parallel, we will use qualitative approaches to evaluate clinician facilitators and barriers to tool utilization as well as patient satisfaction and engagement with the tool.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Atrial Fibrillation

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: through study completion, up to 4 years

Year 4
Clinician and patient feedback on acceptability and identification of barriers and facilitators to use of the tool.
Number of patients appropriately prescribed OACs after CDS tool implementation.

Trial Safety

Safety Progress

1 of 3

Other trials for Atrial Fibrillation

Trial Design

0 Treatment Group

81 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, up to 4 years
Closest Location: Oregon Health & Science University (OHSU) · Portland, OR
Photo of Portland 1Photo of Portland 2Photo of Portland 3
2012First Recorded Clinical Trial
1 TrialsResearching Atrial Fibrillation
18 CompletedClinical Trials

Who is running the clinical trial?

Oregon Health and Science UniversityLead Sponsor
880 Previous Clinical Trials
6,828,248 Total Patients Enrolled
2 Trials studying Atrial Fibrillation
2,386 Patients Enrolled for Atrial Fibrillation
Bory Kea, MD, MCRPrincipal InvestigatorOregon Health and Science University

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.